Atrial fibrillation pathophysiology: Implications for management

Circulation

Volumn 124, Issue 20, 2011, Pages 2264-2274

  Iwasaki, Yu Ki ^a   Nishida, Kunihiro ^a,b   Kato, Takeshi ^a   Nattel, Stanley ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

antiarrhythmia agents; arrhythmia; calcium; electrophysiology; reentry

Indexed keywords

ANTICOAGULANT AGENT; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM CHANNEL L TYPE; CALCIUM ION; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INWARDLY RECTIFYING POTASSIUM CHANNEL; ION CHANNEL; OMEGA 3 FATTY ACID; RANOLAZINE; VERNAKALANT;

ABLATION THERAPY; ACTION POTENTIAL; ARTICLE; CALCIUM CURRENT; CARDIOVERSION; HEART ATRIUM FIBRILLATION; HEART DEPOLARIZATION; HEART LEFT ATRIUM; HEART LEFT ATRIUM STRUCTURE; HEART RATE; HEART RHYTHM; HEART VENTRICLE FUNCTION; HUMAN; PATHOPHYSIOLOGY; POTASSIUM CURRENT; PRIORITY JOURNAL; SINUS RHYTHM; THROMBOEMBOLISM;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DISEASE MANAGEMENT; ELECTROCARDIOGRAPHY; HUMANS;

EID: 81355142736     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.019893     Document Type: Article

References (91)

1. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119-125. (Pubitemid 44420743)
2. Nattel S. New ideas about atrial fibrillation 50 years on. Nature. 2002; 415:219-226. (Pubitemid 34059528)
3. Wakili R, Voigt N, Kaab S, Dobrev D, Nattel S. Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest. 2011;121: 2955-2968.
4. Allessie MA, Boyden PA, Camm AJ, Kléber AG, Lab MJ, Legato MJ, Rosen MR, Schwartz PJ, Spooner PM, Van Wagoner DR, Waldo AL. Pathophysiology and prevention of atrial fibrillation. Circulation. 2001; 103:769-777. (Pubitemid 32144209)
5. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011; 91:265-325.
6. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Métayer P, Clémenty J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339:659-666. (Pubitemid 28402090)
7. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol. 2008;1: 62-73.
8. de Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen RJ, van den Heijkant AC, Allessie MA, Crijns HJ. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol. 2010;55:725-731.
9. de Groot NM, Houben RP, Smeets JL, Boersma E, Schotten U, Schalij MJ, Crijns H, Allessie MA. Electropathological substrate of longstanding persistent atrial fibrillation in patients with structural heart disease: epi-cardial breakthrough. Circulation. 2010;122:1674-1682.
10. Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ, Damiano RJ Jr, Davies DW, Haines DE, Haissaguerre M, Iesaka Y, Jackman W, Jais P, Kottkamp H, Kuck KH, Lindsay BD, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Natale A, Pappone C, Prystowsky E, Raviele A, Ruskin JN, Shemin RJ. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Heart Rhythm. 2007;4:816-861. (Pubitemid 46850611)
11. Stillitano F, Lonardo G, Zicha S, Varro A, Cerbai E, Mugelli A, Nattel S. Molecular basis of funny current (If) in normal and failing human heart. J Mol Cell Cardiol. 2008;45:289-299.
12. Johnson JN, Tester DJ, Perry J, Salisbury BA, Reed CR, Ackerman MJ. Prevalence of early-onset atrial fibrillation in congenital long QT syndrome. Heart Rhythm. 2008;5:704-709.
13. Yeh YH, Wakili R, Qi XY, Chartier D, Boknik P, Kääb S, Ravens U, Coutu P, Dobrev D, Nattel S. Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure. Circ Arrhythm Electrophysiol. 2008;1:93-102.
14. Pizzale S, Gollob MH, Gow R, Birnie DH. Sudden death in a young man with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 2008;19: 1319-1321.
15. Comtois P, Kneller J, Nattel S. Of circles and spirals: bridging the gap between the leading circle and spiral wave concepts of cardiac reentry. Europace. 2005;7(suppl 2):10-20.
16. Dobrev D, Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet. 2010;375:1212-1223.
17. Shiroshita-Takeshita A, Mitamura H, Ogawa S, Nattel S. Rate-dependence of atrial tachycardia effects on atrial refractoriness and atrial fibrillation maintenance. Cardiovasc Res. 2009;81:90-97.
18. Pandit SV, Berenfeld O, Anumonwo JM, Zaritski RM, Kneller J, Nattel S, Jalife J. Ionic determinants of functional reentry in a 2-D model of human atrial cells during simulated chronic atrial fibrillation. Biophys J. 2005;88:3806-3821. (Pubitemid 40991096)
19. Yue L, Xie J, Nattel S. Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Car-diovasc Res. 2011;89:744-753.
20. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008;51:802-809. (Pubitemid 351260071)
21. Burstein B, Comtois P, Michael G, Nishida K, Villeneuve L, Yeh YH, Nattel S. Changes in connexin expression and the atrial fibrillation substrate in congestive heart failure. Circ Res. 2009;105:1213-1222.
22. Akoum N, Daccarett M, McGann C, Segerson N, Vergara G, Kuppahally S, Badger T, Burgon N, Haslam T, Kholmovski E, Macleod R, Mar-rouche N. Atrial fibrosis helps select the appropriate patient and strategy in catheter ablation of atrial fibrillation: a DE-MRI guided approach. J Cardiovasc Electrophysiol. 2011;22:16-22.
23. Burstein B, Qi XY, Yeh YH, Calderone A, Nattel S. Atrial cardiomyocyte tachycardia alters cardiac fibroblast function: a novel consideration in atrial remodeling. Cardiovasc Res. 2007;76:442-452. (Pubitemid 350007456)
24. Chou CC, Chen PS. New concepts in atrial fibrillation: neural mechanisms and calcium dynamics. Cardiol Clin. 2009;27:35-43, viii.
25. Kneller J, Zou R, Vigmond EJ, Wang Z, Leon LJ, Nattel S. Cholinergic atrial fibrillation in a computer model of a two-dimensional sheet of canine atrial cells with realistic ionic properties. Circ Res. 2002;90: E73-E87.
26. Dobrev D, Voigt N, Wehrens XH. The ryanodine receptor channel as a molecular motif in atrial fibrillation: pathophysiological and therapeutic implications. Cardiovasc Res. 2011;89:734-743.
27. Gould PA, Yii M, McLean C, Finch S, Marshall T, Lambert GW, Kaye DM. Evidence for increased atrial sympathetic innervation in persistent human atrial fibrillation. Pacing Clin Electrophysiol. 2006;29:821-829. (Pubitemid 44222134)
28. Tan AY, Zhou S, Ogawa M, Song J, Chu M, Li H, Fishbein MC, Lin SF, Chen LS, Chen PS. Neural mechanisms of paroxysmal atrial fibrillation and paroxysmal atrial tachycardia in ambulatory canines. Circulation. 2008;118:916-925.
29. Nishida K, Maguy A, Sakabe M, Comtois P, Inoue H, Nattel S. The role of pulmonary veins vs. autonomic ganglia in different experimental substrates of canine atrial fibrillation. Cardiovasc Res. 2011;89:825-833.
30. Zhou S, Chang CM, Wu TJ, Miyauchi Y, Okuyama Y, Park AM, Hamabe A, Omichi C, Hayashi H, Brodsky LA, Mandel WJ, Ting CT, Fishbein MC, Karagueuzian HS, Chen PS. Nonreentrant focal activations in pulmonary veins in canine model of sustained atrial fibrillation. Am J Physiol Heart Circ Physiol. 2002;283:H1244-H1252.
31. Po SS, Li Y, Tang D, Liu H, Geng N, Jackman WM, Scherlag B, Lazzara R, Patterson E. Rapid and stable re-entry within the pulmonary vein as a mechanism initiating paroxysmal atrial fibrillation. J Am Coll Cardiol. 2005;45:1871-1877. (Pubitemid 40779870)
32. Ehrlich JR, Cha TJ, Zhang L, Chartier D, Melnyk P, Hohnloser SH, Nattel S. Cellular electrophysiology of canine pulmonary vein cardio-myocytes: action potential and ionic current properties. J Physiol. 2003; 551:801-813. (Pubitemid 37221074)
33. Morel E, Meyronet D, Thivolet-Bejuy F, Chevalier P. Identification and distribution of interstitial Cajal cells in human pulmonary veins. Heart Rhythm. 2008;5:1063-1067.
34. Levin MD, Lu MM, Petrenko NB, Hawkins BJ, Gupta TH, Lang D, Buckley PT, Jochems J, Liu F, Spurney CF, Yuan LJ, Jacobson JT, Brown CB, Huang L, Beermann F, Margulies KB, Madesh M, Eberwine JH, Epstein JA, Patel VV. Melanocyte-like cells in the heart and pulmonary veins contribute to atrial arrhythmia triggers. J Clin Invest. 2009; 119:3420-3436.
35. Hocini M, Ho SY, Kawara T, Linnenbank AC, Potse M, Shah D, Jäs P, Janse MJ, Hässaguerre M, De Bakker JM. Electrical conduction in canine pulmonary veins: electrophysiological and anatomic correlation. Circulation. 2002;105:2442-2448. (Pubitemid 34556399)
36. Nishida K, Sarrazin JF, Fujiki A, Oral H, Inoue H, Morady F, Nattel S. Roles of the left atrial roof and pulmonary veins in the anatomic substrate for persistent atrial fibrillation and ablation in a canine model. J Am Coll Cardiol. 2010;56:1728-1736.
37. Chang SL, Tai CT, Lin YJ, Wongcharoen W, Lo LW, Lee KT, Chang SH, Tuan TC, Chen YJ, Hsieh MH, Tsao HM, Wu MH, Sheu MH, Chang CY, Chen SA. The role of left atrial muscular bundles in catheter ablation of atrial fibrillation. J Am Coll Cardiol. 2007;50:964-973. (Pubitemid 47313599)
38. Tanaka K, Zlochiver S, Vikstrom KL, Yamazaki M, Moreno J, Klos M, Zaitsev AV, Vaidyanathan R, Auerbach DS, Landas S, Guiraudon G, Jalife J, Berenfeld O, Kalifa J. Spatial distribution of fibrosis governs fibrillation wave dynamics in the posterior left atrium during heart failure. Circ Res. 2007;101:839-847. (Pubitemid 350287199)
39. Armour JA, Murphy DA, Yuan BX, Macdonald S, Hopkins DA. Gross and microscopic anatomy of the human intrinsic cardiac nervous system. Anat Rec. 1997;247:289-298. (Pubitemid 27053904)
40. Lemola K, Chartier D, Yeh YH, Dubuc M, Cartier R, Armour A, Ting M, Sakabe M, Shiroshita-Takeshita A, Comtois P, Nattel S. Pulmonary vein region ablation in experimental vagal atrial fibrillation: role of pulmonary veins versus autonomic ganglia. Circulation. 2008;117:470-477.
41. Lin YJ, Tai CT, Kao T, Tso HW, Huang JL, Higa S, Yuniadi Y, Huang BH, Liu TY, Lee PC, Hsieh MH, Chen SA. Electrophysiological characteristics and catheter ablation in patients with paroxysmal right atrial fibrillation. Circulation. 2005;112:1692-1700. (Pubitemid 41368144)
42. Berenfeld O, Zaitsev AV, Mironov SF, Pertsov AM, Jalife J. Frequency-dependent breakdown of wave propagation into fibrillatory conduction across the pectinate muscle network in the isolated sheep right atrium. Circ Res. 2002;90:1173-1180. (Pubitemid 34786902)
43. Wu TJ, Yashima M, Xie F, Athill CA, Kim YH, Fishbein MC, Qu Z, Garfinkel A, Weiss JN, Karagueuzian HS, Chen PS. Role of pectinate muscle bundles in the generation and maintenance of intra-atrial reentry: potential implications for the mechanism of conversion between atrial fibrillation and atrial flutter. Circ Res. 1998;83:448-462. (Pubitemid 28389975)
44. Voigt N, Trausch A, Knaut M, Matschke K, Varró A, Van Wagoner DR, Nattel S, Ravens U, Dobrev D. Left-to-right atrial inward rectifier potassium current gradients in patients with paroxysmal versus chronic atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3:472-480.
45. Sarmast F, Kolli A, Zaitsev A, Parisian K, Dhamoon AS, Guha PK, Warren M, Anumonwo JM, Taffet SM, Berenfeld O, Jalife J. Cholinergic atrial fibrillation: I(K,ACh) gradients determine unequal left/right atrial frequencies and rotor dynamics. Cardiovasc Res. 2003;59:863-873. (Pubitemid 38366242)
46. Lazar S, Dixit S, Marchlinski FE, Callans DJ, Gerstenfeld EP. Presence of left-to-right atrial frequency gradient in paroxysmal but not persistent atrial fibrillation in humans. Circulation. 2004;110:3181-3186. (Pubitemid 39525063)
47. Feng J, Yue L, Wang Z, Nattel S. Ionic mechanisms of regional action potential heterogeneity in the canine right atrium. Circ Res. 1998;83: 541-551. (Pubitemid 28411056)
48. Phan TT, Abozguia K, Shivu GN, Ahmed I, Leyva F, Patel K, Frenneaux M. Increased atrial contribution to left ventricular filling compensates for impaired early filling during exercise in heart failure with preserved ejection fraction. J Card Fail. 2009;15:890-897.
49. Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol. 1992;69:1570-1573.
50. Naito M, David D, Michelson EL, Schaffenburg M, Dreifus LS. The hemodynamic consequences of cardiac arrhythmias: evaluation of the relative roles of abnormal atrioventricular sequencing, irregularity of ventricular rhythm and atrial fibrillation in a canine model. Am Heart J. 1983;106:284-291. (Pubitemid 13028230)
51. Kochiadakis GE, Skalidis EI, Kalebubas MD, Igoumenidis NE, Chrys-ostomakis SI, Kanoupakis EM, Simantirakis EN, Vardas PE. Effect of acute atrial fibrillation on phasic coronary blood flow pattern and flow reserve in humans. Eur Heart J. 2002;23:734-741. (Pubitemid 35230704)
52. Hsu LF, Jais P, Sanders P, Garrigue S, Hocini M, Sacher F, Takahashi Y, Rotter M, Pasquie JL, Scavee C, Bordachar P, Clementy J, Hässaguerre M. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med. 2004;351:2373-2383.
53. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O'Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667-2677. (Pubitemid 351860859)
54. Ehrlich JR, Nattel S, Hohnloser SH. Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets. J Cardiovasc Electrophysiol. 2002; 13:399-405. (Pubitemid 34407608)
55. Nattel S, Opie LH. Controversies in atrial fibrillation. Lancet. 2006;367: 262-272. (Pubitemid 43107672)
56. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet. 2009;373:155-166.
57. Wakili R, Yeh YH, Yan Q, X, Greiser M, Chartier D, Nishida K, Maguy A, Villeneuve LR, Boknik P, Voigt N, Krysiak J, Kaäb S, Ravens U, Linke WA, Stienen GJ, Shi Y, Tardif JC, Schotten U, Dobrev D, Nattel S. Multiple potential molecular contributors to atrial hypocontractility caused by atrial tachycardia remodeling in dogs. Circ Arrhythm Electrophysiol. 2010;3:530-541.
58. Cai H, Li Z, Goette A, Mera F, Honeycutt C, Feterik K, Wilcox JN, Dudley SC Jr, Harrison DG, Langberg JJ. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation. 2002;106:2854-2858. (Pubitemid 35396987)
59. Yamashita T, Sekiguchi A, Iwasaki YK, Sagara K, Hatano S, Iinuma H, Aizawa T, Fu LT. Thrombomodulin and tissue factor pathway inhibitor in endocardium of rapidly paced rat atria. Circulation. 2003;108: 2450-2452. (Pubitemid 37444404)
60. Nattel S. From guidelines to bench: implications of unresolved clinical issues for basic investigations of atrial fibrillation mechanisms. Can J Cardiol. 2011;27:19-26.
61. Kozlowski D, Budrejko S, Lip GY, Rysz J, Mikhailidis DP, Raczak G, Banach M. Lone atrial fibrillation: what do we know? Heart. 2010;96: 498-503.
62. Mont L. Arrhythmias and sport practice. Heart. 2010;96:398-405.
63. Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, Maclehose R, Konety S, Alonso A. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2011; 123:1501-1508.
64. Lubitz SA, Ozcan C, Magnani JW, Kaäb S, Benjamin EJ, Ellinor PT. Genetics of atrial fibrillation: implications for future research directions and personalized medicine. Circ Arrhythm Electrophysiol. 2010;3: 291-299.
65. Ravens U, Wettwer E. Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications. Cardiovasc Res. 2011;89:776-785.
66. Machida T, Hashimoto N, Kuwahara I, Ogino Y, Matsuura J, Yamamoto W, Itano Y, Zamma A, Matsumoto R, Kamon J, Kobayashi T, Ishiwata N, Yamashita T, Ogura T, Nakaya H. Effects of a highly selective acetylcholine-activated K + channel blocker on experimental atrial fibrillation. Circ Arrhythm Electrophysiol. 2011;4:94-102.
67. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation. 2007;116: 1449-1457. (Pubitemid 47480635)
68. Comtois P, Sakabe M, Vigmond EJ, Munoz M, Texier A, Shiroshita-Takeshita A, Nattel S. Mechanisms of atrial fibrillation termination by rapidly unbinding Na+ channel blockers: insights from mathematical models and experimental correlates. Am J Physiol Heart Circ Physiol. 2008;295:H1489-H1504.
69. Skibsbye L, Diness JG, Sorensen US, Hansen RS, Grunnet M. The duration of pacing-induced atrial fibrillation is reduced in vivo by inhibition of small conductance Ca2 +-activated K+ channels. J Cardiovasc Pharmacol. 2011;57:672-681.
70. Cheng Y, Zhan Q, Zhao J, Xiao J. Stabilizing ryanodine receptor type 2: a novel strategy for the treatment of atrial fibrillation. Med Sci Monit. 2010;16:HY23-HY26.
71. Anderson ME. Calmodulin kinase signaling in heart: an intriguing candidate target for therapy of myocardial dysfunction and arrhythmias. Pharmacol Ther. 2005;106:39-55. (Pubitemid 40386719)
72. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation. 2004;110:2313-2319. (Pubitemid 39407332)
73. Shiroshita-Takeshita A, Brundel BJ, Burstein B, Leung TK, Mitamura H, OgawaS, Nattel S. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res. 2007;74:75-84. (Pubitemid 46366949)
74. Sakabe M, Shiroshita-Takeshita A, Maguy A, Dumesnil C, Nigam A, Leung TK, Nattel S. Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. Circulation. 2007;116:2101-2109. (Pubitemid 350060347)
75. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z, Nattel S. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation. 2001;104:2608-2614. (Pubitemid 33104801)
76. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines, part I: primary prevention. Europace. 2011;13:308-328.
77. Gillis AM, Verma A, Talajic M, Nattel S, Dorian P; CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management. Can J Cardiol. 2011;27:47-59.
78. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van Veldhuisen DJ, Van den Berg MP; RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:1363-1373.
79. Verma A, Macle L, Cox J, Skanes AC; CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: catheter ablation for atrial fibrillation/atrial flutter. Can J Cardiol. 2011;27:60-66.
80. Khan A, Mittal S, Kamath GS, Garikipati NV, Marrero D, Steinberg JS. Pulmonary vein isolation alone in patients with persistent atrial fibrillation: an ablation strategy facilitated by antiarrhythmic drug induced reverse remodeling. J Cardiovasc Electrophysiol. 2011;22:142-148.
81. Igarashi M, Tada H, Sekiguchi Y, Yamasaki H, Arimoto T, Kuroki K, Machino T, Murakoshi N, Aonuma K. Effect of restoration of sinus rhythm by extensive antiarrhythmic drugs in predicting results of catheter ablation of persistent atrial fibrillation. Am J Cardiol. 2010;106:62-68.
82. Weerasooriya R, Khairy P, Litalien J, Macle L, Hocini M, Sacher F, Lellouche N, Knecht S, Wright M, Nault I, Miyazaki S, Scavee C, Clementy J, Haissaguerre M, Jais P. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up? J Am Coll Cardiol. 2011;57:160-166.
83. Savelieva I, Camm AJ. Upstream therapies after pulmonary vein ablation: five negative studies: what's next? Europace. 2010;12:1509-1513.
84. Datino T, Macle L, Qi XY, Maguy A, Comtois P, Chartier D, Guerra PG, Arenal A, Fernández-Avilés F, Nattel S. Mechanisms by which adenosine restores conduction in dormant canine pulmonary veins. Circulation. 2010;121:963-972.
85. Katritsis D, Merchant FM, Mela T, Singh JP, Heist EK, Armoundas AA. Catheter ablation of atrial fibrillation the search for substrate-driven end points. J Am Coll Cardiol. 2010;55:2293-2298.
86. O'Neill MD, Jäs P, Takahashi Y, Jönsson A, Sacher F, Hocini M, Sanders P, Rostock T, Rotter M, Pernat A, Clémenty J, Hässaguerre M. The stepwise ablation approach for chronic atrial fibrillation: evidence for a cumulative effect. J Interv Card Electrophysiol. 2006;16:153-167. (Pubitemid 46020551)
87. Katritsis DG, Giazitzoglou E, Zografos T, Pokushalov E, Po SS, Camm AJ. Rapid pulmonary vein isolation combined with autonomic ganglia modification: a randomized study. Heart Rhythm. 2011;8:672-678.
88. Potpara TS, Lip GY. Current therapeutic strategies and future perspectives for the prevention of arterial thromboembolism: focus on atrial fibrillation. Curr Pharm Des. 2010;16:3455-3471.
89. Lam YY, Ma TK, Yan BP. Alternatives to chronic warfarin therapy for the prevention of stroke in patients with atrial fibrillation. Int J Cardiol. 2011;150:4-11.
90. Wang Z, Lu Y, Yang B. MicroRNAs and atrial fibrillation: new fundamentals. Cardiovasc Res. 2011;89:710-721.
91. Amit G, Qin H, Donahue JK. Biological therapies for atrial fibrillation. J Cardiovasc Pharmacol. 2008;52:222-227.